This webinar series is brought to you by the Translational Medicine Group (TMG).
New research implicates Bartonella, the key agents behind Cat Scratch Disease and Trench Fever, in a broad range of chronic symptoms affecting multiple systems of the body – neurologic, rheumatologic and vascular.
In May 2012, a team of veterinary and human medical scientists published in the CDC’s Journal , Emerging Infectious Diseases (EID May 2012), the largest ever case series of Bartonella spp. bacteremic patients in the human medical literature. These patients were examined and selected for testing by Dr. Robert Mozayeni due to concerns about Lyme disease, however, distinct clinical features of small vessel disease were observed. Bartonella appears to be an important co-infection in humans with Borrelia, however, Bartonella sp. can be transmitted by a broad range of vectors that harbor these bacteria. In addition, a broad range of animal hosts serve as persistently infected reservoirs for human infection. Awareness is emerging regarding Bartonella infections in domestic and wild animals and humans. The findings from this study support associations between Bartonella species infection and diagnoses such as Lyme Disease (borreliosis), Rheumatoid Arthritis, Chronic Fatigue Syndrome, and Fibromyalgia.
In this webinar series, co-investigators, Dr. Edward B. Breitschwerdt, DVM, and Dr. B. Robert Mozayeni, MD, present a two-part course for health professionals regarding the biology, diagnosis and treatment of bartonellosis.
FOR HEALTHCARE PROFESSIONALS ONLY
Purchase a 30 day online access pass to the 2 professional webinars
.
.
.
FOR THOSE WHO ARE PET OWNERS, PATIENTS, AND THEIR FAMILIES AND FRIENDS
Purchase a 30 day online access pass to the patient, pet owner, and friends webinar
.
The Translational Medicine Group partners with non-profit foundations to bring you educational programs focused on research and education to support the translation of medical discoveries for health professionals and the public. Webinar Objectives
- Biology of Bartonella spp – hosts, vectors, modes of transmission, cellular tropism.
- Prevalence and importance as a One Health microbe.
- Bartonella epidemiology and evidence supporting persistent bacteremia in immunocompetent and immunocompromised hosts
- Pathogenic mechanism associated with bartonellosis.
- Benefits and limits associated with Bartonella serology, culture, and molecular diagnostic tests.
- Role of Bartonella infection in Lyme Disease patients
- Introduction to small vessel disease caused by endovascular infection, inflammation, and hypercoagulability.
- Clinical manifestations associated with bartonellosis and optimal diagnosis of Bartonella spp infections
- Potential neurovascular and neuropsychiatric manifestations of bartonellosis.
- Review principles of in antibiotic selection and utilization for treatment of bartonellosis.
- Treatment options for Bartonella infections in human patients.
- Clinical experiences based upon patient response and sequential Bartonella testing.
- Time course of treatment and symptom response in Bartonella infection.
- Co-morbidities associated with chronic Bartonella bacteremia, including neurovascular and endocrine problems, and their management.
- Treatment outcomes and suggested protocol for follow-up testing of infected patients.
- Ancillary treatment options.
- Rationale for a Bartonella registry and the importance of tracking treatment results for individual patients.
- Future clinical priorities for Bartonella research.
Speaker Bios
a
Edward B. Breitschwerdt, DVM
Professor of Internal Medicine, NCSU College of Veterinary Medicine Adjunct Professor of Infectious Disease, Duke University Co-founder and Chief Scientific Officer, Galaxy Diagnostics, Inc.
With over 200 peer-reviewed publications, Dr. Breitschwerdt is an internationally recognized leader in the research, diagnosis, and treatment of zoonotic and vector-borne illnesses in companion animals. Most recently, Dr. Breitschwerdt’s research team at the North Carolina State University College of Veterinary Medicine has produced significant research findings concerning the medical importance of Bartonella and other emerging infectious disease pathogens for both animals and humans. Veterinary medicine provides an excellent vantage point from which to study infectious disease across species, especially within the context of the human-animal bond and risk factors for infection.
a
B Robert Mozayeni, MD
Founder, Translational Medicine Group, P.C. Chief Medical Officer, Galaxy Diagnostics, LLC Board of Directors, Center for Translational Medicine
Dr. Mozayeni has actively practiced translational medicine for 23 years in rheumatic diseases, vascular inflammation, cerebrovascular disease, and chronic infections. His honors include Pew Foundation Scholarship in Transplantation Immunology, AOA Honor Medical Society, and National Institutes of Health – Howard Hughes Medical Institute Research Scholar. His post-graduate training began with a Residency in Internal Medicine at the Yale School of Medicine combined with a Fellowships in Molecular Biophysics and Biochemistry and in Rheumatology at the Yale School of Medicine. Then, for three years, he was a Senior Staff Fellow at the National Heart Lung and Blood Institute at the National Institutes of Health (NIH), during which time he was also a Rheumatology Fellow at the National Institute of Arthritis and Musculoskeletal Diseases at the NIH. Dr. Mozayeni has published in the fields of immunology, cerebrovascular medicine, and chronic infections. He holds 8 patents, most with regard to cerebrovascular flow in cognitive impairment. This combined experience led him to discover, using Dr. Breitschwerdt’s Bartonella detection platform, that Bartonella can manifest as small vessel disease with neurovascular manifestations.
The Translational Medicine Group partners with non-profit foundations to bring you educational programs focused on research and education to support the translation of medical discoveries for health professionals and the public.
